Qepler | summits & conferences | Drug/Device Combination Products Summit, Berlin, 4 December 2018
Event Location:
Berlin, Germany
NH Collection Berlin Mitte am Checkpoint Charlie Leipziger Str. 106-111
04 December 2018 - 05 December 2018
Contact Person: Evgenia Makar
Contact Person: Evgenia Makar, Qepler s.r.o.
Contact Person: Denis Polikarpov
Contact Person: Denis Polikarpov, Qepler s.r.o.

Conference Overview

Drug-device combination products represent the next wave of drug delivery devices of increasing complexity. Their development requires a number of technical challenges to consider - integrating drug and device systems, defining the elements of design control, determining quality systems and manufacturing processes. It is also critical to establish a regulatory and clinical strategy from early on in development. Our meeting facilitates a better understanding of both regulatory and practical aspects of developing drug-device combinations, as well as the management of combination products across the total product life cycle.

The featured talks on:

  • Integration of drug and device: combination product mindset
  • How to prioritize different regulations in product development
  • Risk-based approaches to design and development of drug delivery systems
  • Guidelines in design control for combination products
  • Turning user needs into design inputs
  • Human factors validation vs. design validation
  • Design verification strategies
  • Key quality systems expectations during design
  • Biocompatibility evaluation of combination products
  • Stability and shelf-life successful practices
  • Clinical and safety parameters for combination products
  • Technology transfer during lifecycle of combination products
  • Documentation requirements for combination products
  • Best practices for post-approval changes
  • Considerations on legacy products
  • Digitalisation to support combination product development

Meet our Speakers



▸AbbVie ▸Ablynx ▸anteris medical ▸AOP Orphan Pharmaceuticals ▸Astellas Pharma ▸AstraZeneca ▸BIOCORP ▸Biogen ▸Boehringer Ingelheim microParts ▸Bristol-Myers Squibb ▸BSI Group ▸Corvus Device ▸Cytel ▸Design Science ▸Eli Lilly ▸Freelancer ▸GSK ▸H&B Electronic ▸H&T Presspart ▸Hanway Associates ▸Janssen ▸LEO Pharma ▸Maetrics ▸Medac ▸Medtronic ▸Nelson Labs ▸Nelson Labs Europe ▸Novartis ▸Orion Corporation - Orion Pharma ▸Pall Life Sciences ▸Pharmathen ▸Progress-PME ▸Regeneron Pharmaceuticals ▸Sanofi R&D ▸Sanofi-Aventis ▸sfm medical devices ▸Sharp Clinical Services ▸Spiegelberg ▸TERUMO EUROPE ▸tesa Labtec ▸Teva ▸UPM Raflatac


Serge Mathonet

Sanofi R&D

chaired a panel discussion with speakers from TERUMO EUROPE, Novartis, anteris medical GmbH, GlaxoSmithKline, AstraZeneca and Corvus Device.

This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Cookies Policy.